NGHIÊN CỨU MỘT SỐ YẾU TỐ NGUY CƠ VÀ ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ DỰ PHÒNG TÁI PHÁT CƠN ĐAU ĐẦU MIGRAINE BẰNG SODIUM VALPROATE

Abstract

 Background: Migraine is a common disease in the world, many risk factors have been reported. Many studies have proved that the anti-epileptic drug group represented by sodium valproate is effective in the prophylactic treatment of Migraine. Currently, in Vietnam and the Mekong Delta, more research is needed to evaluate the efficacy of sodium valproate in the prophylactic treatment of Migraine. Objective: The aim of this study is to describe some risk factors and evaluate the efficacy of sodium valproate in the prophylactic treatment of Migraine. Materials and methods: a cross-sectional study over 30 patients diagnosed with Migraine headache and suitable for prophylactic treatment at Can Tho Central General Hospital in 2018- 2020. Described some risk factors and evaluated the reduction of pain intensity, frequency of pain, duration of pain and quality of life based on HIT-6 (The six-item Headache Impact Test) after 4 weeks, 8 weeks and 12 weeks. Results: The rate of anxiety disorders, sleep disorders, family history of Migraine were 50%, 46.7% and 6.7%. After three month of treatment, the intensity of pain decreased significantly compared to this in the 4th week and 8th week (p <0.001); The rate of headache reduction after 4 weeks, 8 weeks and 12 weeks were 16.7%, 50%, 90%; The rate of improvement in time of pain after 4 weeks, 8 weeks and 12 weeks were 30%, 63.3%, 83.3%; There was an improvement in the quality of life at 12 weeks compared to the 4th week and the 8th week (p <0.001). Conclusion: Anxiety disorders (50%) and sleep disorders (46.7%) are common in Migraine patients. The improvement in the quality of life of patients has proven after 3 months of migraine prophylaxis.